BG Medicine, Inc. (BG MEDICINE INC) Aktie

BG Medicine, Inc., a diagnostics company, engages in the development and commercialization of novel cardiovascular diagnostic tests to address unmet medical needs in the United States, Europe, and internationally. It offers BGM Galectin-3 test, a novel diagnostic test that measures galectin-3 in blood plasma or serum; and CardioSCORE test that is designed to identify cardiovascular events, such as heart attack and stroke. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was incorporated in 2000 and is headquartered in Waltham, Massachusetts.